

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrDYSPORT AESTHETIC®

abobotulinumtoxinA

Sterile lyophilized powder for solution for injection

300 Units per vial

Neuromuscular Blocking Agent

Ipsen Biopharmaceuticals Canada Inc.
Suite 505, 5060 Spectrum Way
Mississauga, ON
L4W 5N5

Date of Initial Authorization:
FEB 19, 2013

Date of Revision:
JUL 23, 2021

Distributed by: Galderma Canada Inc.
55 Commerce Valley Drive West
Thornhill, ON L3T 7V9

Submission Control Number: 249144

RECENT MAJOR LABEL CHANGES

4 Dosage and Administration, 4.3 Reconstitution	10/2020
---	---------

TABLE OF CONTENTS

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics	4
1.2 Geriatrics	4
2 CONTRAINDICATIONS	4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	4
4 DOSAGE AND ADMINISTRATION	5
4.1 Dosing Considerations	5
4.2 Recommended Dose and Dosage Adjustment.....	5
4.3 Reconstitution	5
4.4 Administration	6
5 OVERDOSAGE	7
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	8
7 WARNINGS AND PRECAUTIONS	8
7.1 Special Populations	10
7.1.1 Pregnant Women	10
7.1.2 Breast-feeding.....	10
7.1.3 Pediatrics	10
7.1.4 Geriatrics	10
8 ADVERSE REACTIONS	10
8.1 Adverse Reaction Overview	10
8.2 Clinical Trial Adverse Reactions.....	10
8.3 Post-Market Adverse Reactions.....	13
9 DRUG INTERACTIONS	14
9.1 Drug Interactions Overview.....	14
9.2 Drug-Drug Interactions.....	14
9.3 Drug-Food Interactions	15
9.4 Drug-Herb Interactions.....	15

9.5	Drug-Laboratory Test Interactions.....	15
10	CLINICAL PHARMACOLOGY.....	15
10.1	Mechanism of Action.....	15
10.2	Pharmacodynamics.....	15
10.3	Pharmacokinetics.....	15
11	STORAGE, STABILITY AND DISPOSAL.....	15
12	SPECIAL HANDLING INSTRUCTIONS.....	16
PART II: SCIENTIFIC INFORMATION		16
13	PHARMACEUTICAL INFORMATION.....	16
14	CLINICAL TRIALS.....	16
14.1	Trial Design and Study Demographics	16
14.2	Study Results.....	18
15	MICROBIOLOGY.....	20
16	NON-CLINICAL TOXICOLOGY.....	20
PATIENT MEDICATION INFORMATION		22

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

DYSPORET AESTHETIC (abobotulinumtoxinA) is indicated for:

- The temporary improvement in the appearance of
 - moderate to severe glabellar lines and/or
 - moderate to severe lateral canthal lines (crow's feet) in adult patients < 65 years of age

1.1 Pediatrics

Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

Geriatrics (> 65 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use.

2 CONTRAINDICATIONS

DYSPORET AESTHETIC is contraindicated in patients:

- who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).
- with infection at the proposed injection sites.
- known to be allergic to cow's milk protein.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

- **DISTANT SPREAD OF TOXIN EFFECT:** The effects of DYSPORET AESTHETIC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.
- The term "Unit" upon which dosing is based, is a specific measurement of toxin activity that is unique to Ipsen's formulation of abobotulinumtoxinA. Therefore, the units used to describe DYSPORET AESTHETIC activity are different from those used to describe that of other botulinum toxin preparations and the units representing DYSPORET AESTHETIC activity are not interchangeable with other products.
- DYSPORET AESTHETIC should only be administered by physicians with the appropriate qualifications and experience in the treatment and the use of required equipment.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- For Intramuscular Use Only.
- The potency units of DYSPORT AESTHETIC are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT AESTHETIC cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.
- Treatment should be administered at the recommended dose for each treatment area.
- Injection intervals of DYSPORT AESTHETIC should be no more frequent than every three months.

4.2 Recommended Dose and Dosage Adjustment

Glabellar Lines (GL)

Ten (10) Units should be injected intramuscularly at each of five injection sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 50 Units (see [Figure 1](#)).

Lateral Canthal Lines (LCL)

Ten (10) Units should be injected intramuscularly at each of three injection sites for a total dose of 30 Units per side (a total of 60 Units for both sides; see [Figure 1](#)).

The clinical effect of DYSPORT AESTHETIC may last up to four months. Repeat dose clinical studies demonstrated continued efficacy with up to four repeated administrations.

The treatment interval depends on the individual patient's response after assessment by healthcare practitioners.

Treatment interval should not be more frequent than every three months.

Health Canada has not authorized an indication for pediatric use.

4.3 Reconstitution

Parenteral Products:

DYSPORT AESTHETIC is supplied as a single-use vial.

Each 300 Unit vial of DYSPORT AESTHETIC is to be reconstituted with either 1.5, 2.5 or 3.0 mL of 0.9% sterile, preservative-free, saline prior to injection. The concentration of the resulting solution will be 20 Units per 0.1 mL, 12 Units per 0.1 mL or 10 Units per 0.1 mL respectively (see [Table 1](#)).

Table 1 - Reconstitution

Vial Size	Volume of Diluent to be Added to Vial	Target concentration Units/0.1 mL
300 Unit	1.5 mL	20.0
300 Unit	2.5 mL	12.0
300 Unit	3.0 mL	10.0

Using a 21 gauge needle and aseptic technique, draw up sterile, preservative-free 0.9% saline. Insert the needle into the DYSPORE AESTHETIC vial. The partial vacuum will begin to pull the saline into the vial. Any remaining required saline should be expressed into the vial manually. Do not use the vial if no vacuum is observed. Gently rotate the vial (do not shake), until the white substance is fully dissolved. Reconstituted DYSPORE AESTHETIC should be a clear, colorless solution, free of particulate matter.

Draw DYSPORE AESTHETIC into a sterile syringe. Expel any air bubbles in the syringe barrel. Remove the needle used to reconstitute the product and attach a suitable gauge needle.

Once reconstituted, DYSPORE AESTHETIC should be stored in a refrigerator at 2–8°C protected from light and used within 24 hours. Do not freeze reconstituted DYSPORE AESTHETIC. Discard the vial and needle in accordance with local regulations.

4.4 Administration

The recommended injection points for GLs and LCLs are described below. Ensure the injected volume/dose is accurate.




Figure 1: Glabellar Lines and Lateral Canthal Lines injection points

Glabellar lines:

Glabellar facial lines arise from the activity of the lateral corrugator and vertical procerus muscles. These can be readily identified by palpating the tensed muscle mass while having the patient frown. The corrugator depresses the skin creating a “furrowed” vertical line surrounded by tensed muscle (i.e., frown lines). The location, size, and use of the muscles vary markedly among individuals. Physicians administering DYSPORE AESTHETIC must understand the relevant neuromuscular and/or orbital anatomy of the area involved and any alterations to the anatomy due to prior surgical procedures.

Risk of ptosis can be mitigated by careful examination of the upper lid for separation or weakness of the levator palpebrae muscle (true ptosis), identification of lash ptosis, and evaluation of the range of lid excursion while manually depressing the frontalis to assess compensation.

In order to reduce the complication of ptosis, the following steps should be taken:

- Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes.
- Medial corrugator injections should be placed at least one centimeter above the bony supraorbital ridge.
- Ensure the injected volume/dose is accurate.
- Do not inject toxin closer than 1 centimeter above the central eyebrow.

To inject DYSPORE AESTHETIC, advance the needle through the skin into the underlying muscle while applying finger pressure on the superior medial orbital rim. Inject patients with the recommended dose in five equally divided aliquots using a 30 gauge needle; two in each corrugator muscle and one in the procerus muscle (see [Figure 1](#)).

Lateral Canthal Lines:

Injection should be lateral (at 20-30° angle to the skin) and superficial, avoiding blood vessels. All injection points should be at the external part of the orbicularis oculi muscle and sufficiently far from the orbital rim (approximately 1 - 2 cm from the external orbital rim) and injection points 1 cm apart as shown in [Figure 1](#).

The anatomical landmarks can be more readily identified if observed and palpated at maximal smile. Care must be taken to avoid injecting the zygomaticus major/minor muscles to avoid lateral mouth drop and asymmetrical smile.

5 OVERDOSAGE

Excessive doses of DYSPORE AESTHETIC may be expected to produce neuromuscular weakness with a variety of symptoms. Respiratory support may be required where excessive doses cause paralysis of respiratory muscles. In the event of overdose, the patient should be medically monitored for symptoms of excessive muscle weakness or muscle paralysis. Symptomatic treatment may be necessary.

Symptoms of overdose are not likely to be present immediately following injection. Should accidental injection or oral ingestion occur, the person should be medically supervised for several weeks for signs and symptoms of excessive muscle weakness or paralysis.

In the event of suspected or actual cases of botulinum toxin poisoning, please contact your local Health Department to process a request for antitoxin. However, the antitoxin will not reverse any botulinum toxin-induced effects already apparent by the time of antitoxin administration.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

To help ensure the traceability of biologic products, including biosimilars, health professionals should recognize the importance of recording both the brand name and the non-proprietary (abobotulinumtoxinA) name as well as other product-specific identifiers such as the Drug Identification Number (DIN) and the batch/lot number of the product supplied.

Table 2 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Intramuscular	Sterile, lyophilized powder for reconstitution with 0.9% Sodium Chloride Injection USP (without preservative); 300 Units per vial	125 micrograms human serum albumin and 2.5 mg lactose monohydrate

DYSPORET AESTHETIC is supplied as a single-use sterile 300 Unit vial for reconstitution with 0.9% Sodium Chloride Injection USP (without preservative). Each vial contains 300 Units of lyophilized abobotulinumtoxinA, 125 micrograms human serum albumin and 2.5 mg lactose monohydrate.

7 WARNINGS AND PRECAUTIONS

Please see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#).

General

Use DYSPORET AESTHETIC only as directed.

Do not use dosage recommendations and potency units applied to other botulinum toxin products when using DYSPORET AESTHETIC. Do not exceed the recommended dosage and frequency of administration of DYSPORET AESTHETIC.

The safe and effective use of DYSPORET AESTHETIC depends upon proper storage of the product, selection of the correct dose, reconstitution, and injection technique.

Caution should be exercised when administering DYSPORET AESTHETIC to patients with neuromuscular junction disorders or when excessive weakness or atrophy is present in the target muscle, prolonged bleeding times, surgical alterations to the facial anatomy, marked facial asymmetry, inflammation at the injection site(s), ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin.

Muscle weakness remote to the site of injection and other serious adverse effects (e.g., dysphagia when injected into the neck region) have been very rarely reported in the administration of DYSPORET AESTHETIC. Patients with a history of underlying neurologic disorders, dysphagia and/or aspiration are at a greater risk of these effects and should be treated with extreme caution. The botulinum toxin product should be used under specialist supervision in these patients and should only be used if the benefit of treatment is considered to outweigh the risk.

Patients or caregivers should be advised to seek immediate medical care if swallowing, speech or respiratory disorders arise. Injection intervals of DYSPORT AESTHETIC should be no more frequent than every three months. Indication-specific dosage and administration recommendations should be followed.

This product contains human serum albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. The theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.

Carcinogenesis and Mutagenesis

Animal studies to evaluate the carcinogenic and genotoxic potential of DYSPORT AESTHETIC have not been conducted. (See **16 NON-CLINICAL TOXICOLOGY** section for more information).

Cardiovascular

In study 06-01, 79 subjects were assessed by EKG for treatment-related QT interval changes. Following the use of DYSPORT AESTHETIC for the treatment of GLs, no QT/QTc prolongation was observed.

Driving and Operating Machinery

The potential risk of localized muscle weakness or visual disturbances linked with the use of DYSPORT AESTHETIC may temporarily impair the ability to drive or operate machinery.

Immune

Injections at more frequent intervals or at higher doses can increase the risk of antibody formation to botulinum toxin. Clinically, the formation of neutralizing antibodies may reduce the effectiveness of subsequent treatment. As with all biologic products, an anaphylactic reaction may occur. Necessary precautions should be taken and epinephrine should be available.

Neurologic

Caution should be exercised when administering DYSPORT AESTHETIC to individuals with peripheral motor neuropathy (e.g., amyotrophic lateral sclerosis or motor neuropathy), facial palsy or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome). Patients with neuromuscular disorders may be at an increased risk of clinically significant systemic effects such as severe dysphagia and respiratory compromise.

Ophthalmologic

Caution should be exercised when administering DYSPORT AESTHETIC to individuals with eye disorders, including dry eye and eyelid oedema.

Risk of ptosis can be mitigated by careful examination of the upper lid for separation or weakness of the levator palpebrae muscle (true ptosis), identification of lash ptosis, and evaluation of the range of lid excursion while manually depressing the frontalis to assess compensation.

The potential risk of localized muscle weakness or visual disturbances linked with the use of DYSPORT AESTHETIC may temporarily impair the ability to drive or operate machinery.

Skin

Caution should be exercised when administering DYSPORT AESTHETIC to patients with inflammation at the injection site(s), deep dermal scarring, or thick sebaceous skin.

7.1 Special Populations

7.1.1 Pregnant Women

There are limited data from the use of abobotulinumtoxinA in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/fetal development, parturition or postnatal development other than at high doses causing maternal toxicity. The potential risk to pregnant women is unknown. DYSPORT AESTHETIC should be used during pregnancy only if the benefit justifies any potential risk to the fetus. Caution should be exercised when prescribing to pregnant women.

7.1.2 Breast-feeding

It is not known whether this drug is excreted in human milk. The excretion of DYSPORT AESTHETIC in milk has not been studied in animals. The use of DYSPORT AESTHETIC during lactation is not recommended.

7.1.3 Pediatrics

Pediatrics (< 18 years): DYSPORT AESTHETIC is not recommended for use in children.

7.1.4 Geriatrics

Geriatrics (> 65 years of age): The clinical data for subjects > 65 years of age are limited.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

Adverse reactions may occur within the first few days following injection and while generally transient may have a duration of several months.

Local muscle weakness represents the expected pharmacological action of botulinum toxin in muscle tissue; however, weakness of adjacent muscles associated with local diffusion and/or injection technique has been reported. Muscle weakness remote to the site of injection and other serious adverse effects (e.g., dysphagia when injected into the neck region) have been very rarely reported in the administration of DYSPORT AESTHETIC.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Glabellar Lines (GLs)

Six clinical studies, including one Phase 2, three Phase 3, and two long-term safety studies were conducted with DYSPORT AESTHETIC.

The adverse event data described below reflect exposure in 2,341 subjects who received 5,360 DYSPORT AESTHETIC or placebo treatments (4,880 DYSPORT AESTHETIC; 480 placebo). Some subjects received up to seven treatments with DYSPORT AESTHETIC. The population was composed of subjects 19-80 years of age, and included 263 males and 2,078 females. Most subjects were Caucasian (79.8%). Subjects received 50-80 Unit doses of DYSPORT AESTHETIC, injected intramuscularly in the glabellar region.

Adverse events of any cause were reported for 42% of the subjects treated with DYSPORT AESTHETIC and 29% of the subjects treated with placebo. Treatment-emergent adverse events (TEAEs) were generally mild to moderate in severity and the majority of events were considered unrelated or unlikely to be related to treatment. The most frequently reported adverse events were nasopharyngitis, headache, injection site pain, upper respiratory tract infection, and sinusitis. Subjects re-treated with DYSPORT AESTHETIC demonstrated a comparable safety profile to that of the initial treatment. Table 3 displays treatment-emergent adverse events reported in >1% of subjects, regardless of causality. Repeat dose clinical studies have demonstrated safety for up to seven administrations of DYSPORT AESTHETIC.

Table 3: Treatment-Emergent Adverse Events with > 1% Incidence in the glabellar region

Adverse Events by Preferred Term	DYSPORT AESTHETIC n=2041 (%)*	Placebo n=480 (%)*
Subjects with at least one treatment-emergent adverse event	852 (42)	141 (29)
Eye disorders		
Eyelid ptosis	33 (2)	1 (<1)
General disorders and administration site conditions		
Injection site pain	69 (3)	7 (1)
Injection site bruising	34 (2)	7 (1)
Infections and Infestations		
Nasopharyngitis	123 (6)	19 (4)
Upper respiratory tract infection	58 (3)	4 (<1)
Sinusitis	55 (3)	4 (<1)
Influenza	31 (2)	3 (<1)
Nervous System Disorders		
Headache	110 (5)	16 (3)

* Subjects who received treatment with placebo and DYSPORT AESTHETIC are counted in both treatment columns.

The frequency of any ocular adverse events in the DYSPORT AESTHETIC treatment group was low and decreased with subsequent treatments. The majority of eyelid ptosis events were mild to moderate in severity and resolved over several weeks. The incidence of eyelid ptosis did not increase in the long-term safety studies with multiple re-treatments at intervals \geq three

months.

The frequency of any ocular TEAE in the DYSPORT AESTHETIC treatment group is low in Cycle 1 (3%), decreases to 2% in Cycles 2 and 3, and to 1% in Cycles 4 and 5.

Testing for antibodies to DYSPORT AESTHETIC was performed in 1554 subjects who had up to nine cycles of treatment. Two subjects (0.13%) tested positive for binding antibodies at baseline. Three additional subjects tested positive for binding antibodies after receiving DYSPORT AESTHETIC treatment. None of the subjects tested positive for neutralizing antibodies.

Lateral Canthal Lines (LCLs)

One dose-ranging Phase 2 and one Phase 3 (with an open label safety extension period) studies were conducted with DYSPORT AESTHETIC. The population was composed of subjects 25-69 years of age and included 53 males and 500 females. Most of the subjects were Caucasian (99%) and received DYSPORT AESTHETIC injected intramuscularly, as shown in Figure 1.

In the Phase 2 study, subjects were treated per eye region in LCLs, including 55 subjects with 15 U, 54 subjects with 30 U, 55 subjects with 45 U of DYSPORT AESTHETIC (at 5, 10 and 15 U per injection site, respectively) and 54 subjects received placebo.

The Phase 3 study comprised two parts: Part A, 252 subjects received a single treatment of the recommended 30 U per eye (at 10 U per injection site) in LCLs and 83 subjects received placebo; and Part B, (active treatment only), 315 subjects entered the safety extension period up to 40 weeks with treatments in LCLs with or without concomitant treatment of the GLs. A total of 271 subjects received 3 cycles of active treatment for LCLs (30 U per eye), including 121 patients with 3 cycles of concomitant treatment in GLs (at recommended 50 U) up to a maximum of 110 U per treatment.

Adverse events of any cause were reported for 19% of the subjects treated with DYSPORT AESTHETIC and 16.1% of the subjects treated with placebo.

TEAEs were generally mild to moderate in severity and the majority of events were considered unrelated or unlikely to be related to treatment. TEAEs considered being treatment related included eyelid oedema, headache and injection site reactions (haematoma, pruritus, and swelling).

Table 4: Treatment-Emergent Adverse Events with > 1% Incidence following first cycle of treatment from both studies in the LCLs region at 30 U.

Adverse Events by Preferred Term	DYSPORT AESTHETIC n=306 (%)	Placebo n=137 (%)
Eye disorders		
Eyelid oedema	5 (1.6%)	-
General disorders and administration site conditions		
Injection site reactions (e.g. haematoma, pruritus and swelling)	7 (2.4%)	1 (0.7%)

Infections and Infestations		
Nasopharyngitis	5 (1.7%)	3 (2.2%)
Nervous System Disorders		
Headache	13 (4.3%)	3 (2.2%)

During Part B of the Phase 3 study, subjects re-treated with DYSPO RT AESTHETIC demonstrated a comparable safety profile to that of the initial treatment. Treatment-related TEAEs that were most frequent reported by more than two subjects were headache (4.0%), injection site haematoma (2.1%) and eyelid oedema (1.8%).

Less frequently reported TEAEs were facial paresis (0.9%) and eyelid ptosis (0.9%). Other rare related TEAEs included asthenopia (0.3%), photophobia (0.3%), blurred vision (0.6%), erythema of the eyelid (0.3%), and increased lacrimation (0.3%) and periorbital haematoma (0.7%). Most TEAEs were mild to moderate in intensity.

Testing for antibodies against abobotulinumtoxinA was performed for 332 subjects. No subjects tested were positive for neutralizing antibodies after receiving multiple treatments with DYSPO RT AESTHETIC over one year.

8.3 Post-Market Adverse Reactions

There is extensive post-marketing experience for the treatment of upper facial lines. Adverse reactions are reported voluntarily from a population of uncertain size; thus, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.

Adverse reactions reported during post-marketing without distinction of indications and not reflected elsewhere in the Product Monograph include the following:

Table 5: Adverse Reactions reported during post-marketing without distinction of indication

System Organ Class	Adverse Drug Reaction
Ear and labyrinth disorders	Vertigo
Eye disorders	Diplopia, Dry eye
Gastrointestinal disorders	Dysphagia, Nausea
General disorders	Asthenia, Malaise
Immune system disorders	Hypersensitivity
Investigations	Neutralizing antibodies
Nervous system disorders	Amyotrophy, Burning sensation, Dizziness, Dysarthria Hypoesthesia
Renal and Urinary Disorders	Urinary incontinence
Respiratory, thoracic and mediastinal disorders	Dysphonia, Dyspnea
Skin and subcutaneous tissue disorders	Erythema, Excessive granulation tissue, Urticaria

Antibody formation to botulinum toxin has been noted in patients receiving DYSPO RT AESTHETIC. Clinically, neutralizing antibodies might be suspected by a substantial deterioration in response to therapy and/or the need for consistent use of increased doses (See **7.WARNINGS AND PRECAUTIONS-Immune**).

Adverse effects resulting from distribution of the effects of the toxin to sites remote from the site of injection have been very rarely reported.

9 DRUG INTERACTIONS

9.1 Drug Interactions Overview

No specific interactions have been reported.

No formal drug interaction studies have been conducted with DYSPORE AESTHETIC.

Patients treated concomitantly with botulinum toxins and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents) should be observed closely because the effect of the botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of DYSPORE AESTHETIC may potentiate systemic anticholinergic effects such as blurred vision.

The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of DYSPORE AESTHETIC.

9.2 Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 6 – Established or Potential Drug-Drug Interactions

Proper name of drug	Source of Evidence	Effect	Clinical comment
aminoglycoside antibiotics or other medicinal products that interfere with neuromuscular transmission (e.g., curare-like agents, lincosamides, polymyxins, and anticholinesterases)	T	Theoretically, the effect of botulinum toxin may be potentiated.	The effect of botulinum toxin may be potentiated by aminoglycoside antibiotics or other drugs that interfere with neuromuscular transmission. Caution should be exercised when DYSPORE AESTHETIC is used with aminoglycosides or any other drugs that interfere with neuromuscular transmission.
Different botulinum neurotoxin serotypes	T	Unknown	The effect of administering different botulinum neurotoxin serotypes at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Legend: T = Theoretical

9.3 Drug-Food Interactions

Interactions with food have not been established.

9.4 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.5 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

DYSPORE AESTHETIC inhibits release of the neurotransmitter, acetylcholine, from peripheral cholinergic nerve endings. Toxin activity occurs in the following sequence: Toxin heavy chain mediated binding to specific surface receptors on nerve endings, internalization of the toxin by receptor mediated endocytosis, pH-induced translocation of the toxin light chain to the cell cytosol and cleavage of SNAP25 leading to intracellular blockage of neurotransmitter exocytosis into the neuromuscular junction. This accounts for the therapeutic utility of the toxin in diseases characterized by excessive efferent activity in motor nerves.

Recovery of transmission occurs gradually as the neuromuscular junction recovers from SNAP25 cleavage and as new nerve endings are formed.

10.2 Pharmacodynamics

The primary pharmacodynamic effect of DYSPORE AESTHETIC is due to chemical denervation of the treated muscle resulting in a measurable decrease of the compound muscle action potential, causing a localized reduction of muscle activity.

10.3 Pharmacokinetics

DYSPORE AESTHETIC is not expected to be present in the peripheral blood at measurable levels following intramuscular injection at the recommended doses. Using currently available analytical technology, it is not possible to detect DYSPORE AESTHETIC in the peripheral blood following intramuscular injection at the recommended doses.

Duration of Effect

The clinical effect of DYSPORE AESTHETIC may last up to 4 months. DYSPORE AESTHETIC should not be administered more frequently than every three months. When used for re-treatment, DYSPORE AESTHETIC should be reconstituted and injected using the same techniques as the initial treatment.

11 STORAGE, STABILITY AND DISPOSAL

DYSPORE AESTHETIC must be stored under refrigeration at 2–8°C. Protect from light.

Administer DYSPORE AESTHETIC within 24 hours of reconstitution; during this period reconstituted DYSPORE AESTHETIC should be stored under refrigeration at 2–8°C. Do not freeze after reconstitution.

Do not use after the expiration date on the vial.

12 SPECIAL HANDLING INSTRUCTIONS

All vials, including unused product remaining and expired vials, or equipment used with DYSPORE AESTHETIC should be disposed of carefully as is done with all medical waste.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: abobotulinumtoxinA

Chemical name: Botulinum toxin type A

Molecular formula and molecular mass: AbobotulinumtoxinA is produced as a 150 kDa single polypeptide chain composed of 1296 amino acid residues (1295 after cleavage of the N-terminal methionine). After synthesis, the neurotoxin is proteolytically cleaved to generate a di-chain protein composed of a heavy chain (~80 kDa) and light chain (~50 kDa). On a genetic level, the toxin gene occurs in a cluster of genes which also encode for the non-toxic non-hemagglutinin protein (NTNH), a regulator protein and the hemagglutinin (HA) proteins (HA70, HA34 and HA17). These proteins and their derivatives, except for the regulator protein, form the components of the neurotoxin type A complex.

Structural formula: AbobotulinumtoxinA (Botulinum toxin type A), the active ingredient in DYSPORE AESTHETIC is a purified neurotoxin type A complex produced by fermentation of the bacterium *Clostridium botulinum* type A, Hall Strain. It is purified from the culture supernatant by a series of precipitation, dialysis, and chromatography steps.

Pharmaceutical standard: Ph. Eur.

Product Characteristics:

DYSPORE AESTHETIC uses a cell-based assay to determine the potency of the product relative to a reference material. The assay and reference material are specific to DYSPORE AESTHETIC. One unit of DYSPORE AESTHETIC corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. Due to specific details of the assay system, such as vehicle, dilution scheme and laboratory protocols, units of biological activity of DYSPORE AESTHETIC are not interchangeable with units of any other botulinum toxin or any toxin assessed with any other specific assay method.

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

Glabellar Lines (GLs)

Two double-blind, randomized, placebo-controlled, Phase 3 clinical studies (Study 791 and Study 085) evaluated the efficacy of DYSPORE AESTHETIC for use in the improvement of the appearance of moderate to severe GLs (Table 7). Investigator/Blinded Evaluators assessed efficacy by using a validated 4-point scale (none, mild, moderate, severe). Subjects assessed

efficacy by using a similar static 4-point scale. These two studies enrolled ethnically-diverse, healthy adults (ages 19–75) with GLs of at least moderate severity at maximum frown. Subjects were excluded if they had marked ptosis, deep dermal scarring, or a substantial inability to lessen GLs, even by physically spreading them apart. The subjects in these studies received either DYSPORT AESTHETIC (n=172) or placebo (n=117). The total dose was delivered in equally divided aliquots to specified injection sites (see Figure 1).

Treatment success for each of the Phase 3 studies was defined as post-treatment GL severity of none or mild (from moderate or severe at baseline) at maximum frown.

After completion of the randomized studies, subjects were offered participation in a three-year, open-label re-treatment study to assess the safety of multiple treatments.

Table 7 - Summary of patient demographics for clinical trials in glabellar lines

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
719	A phase 3, randomized, placebo-controlled, multicenter, double-blind study	DYSPORT AESTHETIC 50 Units administered in five aliquots of 10 Units/0.05 mL; single dose (see Figure 1) Placebo 180 days	158 subjects	43 years	135 Female 23 Male
085	A phase 3, randomized, placebo-controlled, multicenter, double-blind study	DYSPORT AESTHETIC 50 Units administered in five aliquots of 10 Units/0.05 mL; multiple doses (see Figure 1) Placebo	311 subjects into the first treatment cycle and; 142 subjects randomized into the final treatment cycle	47 years	269 Female 42 Male

Study 719

Study 719 was a single dose, double-blind, multicenter, randomized, placebo-controlled study in which 158 previously untreated subjects received either placebo or 50 Units of DYSPORT AESTHETIC™ administered in five aliquots of 10 Units/0.05 mL (see Figure 1). Subjects were followed for 180 days. The mean age was 43 years; most of the subjects were women (85%), and predominantly Caucasian (49%) or Hispanic (47%).

Study 085

Study 085 was a repeat dose, double-blind, multicenter, placebo-controlled, randomized study to evaluate the efficacy of repeat dosing. The study was initiated with up to two open-label treatment cycles. After open-label treatment(s), subjects were randomized to receive either placebo or 50 Units of DYSPORT AESTHETIC. Subjects receiving DYSPORT AESTHETIC in the previous cycle, were invited to participate in the final treatment cycle, and were randomized

to receive either placebo or 50 Units of DYSPORT AESTHETIC. Subjects could have received up to four treatments through the course of the study.

The study enrolled 311 subjects into the first treatment cycle and 142 subjects were randomized into the final treatment cycle. Subjects received either placebo or 50 Units of DYSPORT AESTHETIC™ administered in five aliquots of 10 Units/0.05 mL (see Figure 1). Overall, the mean age was 47 years; most of the subjects were women (86%) and predominantly Caucasian (80%). The primary efficacy endpoint was assessed in the final treatment cycle.

Lateral Canthal Lines (LCLs)

One double-blind, randomized, placebo-controlled, Phase 3 clinical study (Study RD.03.SRE.40131) evaluated the efficacy of DYSPORT AESTHETIC for use in the temporary improvement in the appearance of moderate to severe LCLs at maximum smile. Investigator assessed efficacy using a validated 4-point scale (none, mild, moderate, severe), whereas subject’s satisfaction with the appearance of their LCLs was assessed as a secondary endpoint using a 4-level rating (very satisfied, satisfied, dissatisfied, very dissatisfied). Treatment success was defined as the proportion of responders at Week 4 on the severity of LCLs as none or mild at maximum smile. Duration of effect compared with placebo was assessed up to Week 16.

A total of 335 subjects were randomised in a 3:1 ratio to abobotulinumtoxinA (252 subjects) and placebo (83 subjects) and received the recommended dose of 30 Units per side (Part A). A subset of 241 subjects had moderate to severe canthal lines at rest prior to treatment. After 12 weeks post administration, 315 of those subjects participated in the open label safety extension period of the study in which they could be treated concomitantly for both LCLs and GLs up to 40 weeks (Part B).

14.2 Study Results

Studies related to Glabellar Lines (GLs)

Study 719

In study 719, the reduction of GL severity at maximum frown was greater at Day 30 in the DYSPORT AESTHETIC group compared to the placebo group as assessed by both Investigators and subjects (see Table 9).

A majority of DYSPORT AESTHETIC-treated subjects (56.3%) demonstrated a 2+ grade composite (a reduction in the glabellar line severity score by a minimum of 2 grades as assessed by both the Investigator/Blinded Evaluator and subject) improvement, at maximum frown, at Day 30. Onset of effect was reported as soon as 24 hours; the median time to onset of treatment response was three days.

Table 9 - Results of study 719: Investigators’ and Subjects’ Assessment of Glabellar Line Treatment Success at Maximum Frown (using 4-point scale) Following a 50 Unit Dose (% and Number of Responders/Number Assessed)

Day	Investigators		Subjects	
	DYSPORT AESTHETIC	Placebo	DYSPORT AESTHETIC	Placebo
14	94.1%*	19.6%	81.0%*	10.9%

	95/101	9/46	81/100	5/46
30	89.3%* 92/103	3.9% 2/51	75.7%* 78/103	9.8% 5/51
60	66.3%* 67/101	2.0% 1/50	62.4%* 63/101	6.0% 3/50
90	46.4%* 45/97	6.4% 3/47	39.2%* 38/97	6.4% 3/47
120	24.2%† 24/99	4.1% 2/49	20.2%‡ 20/99	6.1% 3/49
150	9.5% 9/95	2.2% 1/45	8.3% 8/96	4.4% 2/45
180	6.3% 6/96	0% 0/46	7.3% 7/96	8.7% 4/46

*p<0.001; †p=0.002; ‡p=0.027

Study 085

The primary efficacy endpoint was assessed in the final treatment cycle. After the final repeat treatment with DYSPORT AESTHETIC, the reduction of GL severity at maximum frown was statistically greater at Day 30 in the DYSPORT AESTHETIC group compared to the placebo group (p<0.001) as assessed by both Investigators and subjects (see Table 10).

A majority of DYSPORT AESTHETIC-treated subjects (52.1%) demonstrated a 2+ grade composite improvement, at maximum frown, at Day 30. Onset of effect was reported as soon as 24 hours; the median time to onset of treatment response was three days.

The proportion of responders in the final treatment cycle was comparable to the proportion of responders in all prior treatment cycles. There was no evidence of reduced response or an increase in adverse events with repeated exposure.

Table 10: Study 085: Proportion of Responders, at Day 30, Using Investigator's and Subject's Assessments of Glabellar Line Treatment Success at Maximum Frown (using 4-point scale) for the Final Treatment Cycle (% and Number of Responders/Number Assessed)

	DYSPORT AESTHETIC	Placebo
Investigator	84.5%* 60/71	4.2% 3/71
Subject	78.9%* 56/71	1.4% 1/71

* p< 0.001

Study related to Lateral Canthal Lines

Study RD.03.SRE.40131

In Study RD.03.SRE.40131, at Week 4, DYSPORT AESTHETIC injections significantly reduced the severity of LCLs compared with placebo (p≤0.001) at maximum smile (Table 11). The proportion of Responders at Week 4, assessed by the Investigator was 47.2% versus

7.2% for subjects who received Placebo.

At week 4, the proportion of DYSPORT AESTHETIC-treated subjects reporting satisfied or very satisfied with the appearance of their LCLs was 65.5% and 16.9% for placebo-treated subjects. Among them, the proportion of DYSPORT AESTHETIC-treated subjects reporting very satisfied was 17.5% and 1.2% for placebo-treated subjects.

At Week 8, the proportion of responders as assessed by the investigator was 37.7% for subjects treated with DYSPORT AESTHETIC versus 4.8% for subjects who received placebo. At Week 12, the proportion of responders was 11.5% with DYSPORT AESTHETIC versus 0% for subjects who received placebo.

In Part A of the study it was shown that DYSPORT AESTHETIC reduced the severity of LCLs seen at maximum smile for up to 12 weeks, the time-point when subjects were offered a re-treatment and entered Part B of the study. The median time to re-treatment with DYSPORT AESTHETIC for treatment cycles of 2 to 5 varied between 12 to 15 weeks interval.

Table 11: Proportion of Responders at Week 4, Using Investigator's Assessments of Canthal Line Treatment Success at Maximum Frown (using 4-point scale) (% and Number of Responders/Number Assessed)

	DYSPORT AESTHETIC	Placebo
Investigator	47.2%	7.2%
	119/252	6/83
Difference with placebo	40%	
p-value (Mantel-Haenszel test)	p< 0.001	
95% Confidence Interval	31.7%, 48.3%	

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

Carcinogenicity: Studies to evaluate the carcinogenic potential of DYSPORT AESTHETIC have not been conducted.

Genotoxicity: Genotoxicity studies have not been conducted with DYSPORT AESTHETIC.

Reproductive and Developmental Toxicology: In a study evaluating postnatal effects, pregnant rats were given weekly doses of 1, 2.5, 5 and 10 Units from Day 6 of gestation through weaning of the litters (21 days postpartum). There was no effect of treatment on in utero survival. Evaluation of the offspring showed no effects on survival, body weights, sexual maturation, post-weaning development, mating performance or fertility. All offspring appeared

normal.

Fertility and Reproductive Toxicity: DYSPORT AESTHETIC had no effect upon fertility when administered intramuscularly to rats at weekly doses up to 16 Units in females, and 10 Units in males. There were no effects upon implantation parameters at doses up to and including 8 Units. Mating was impaired at the high dose (10 Units for males and 16 Units for females), likely due to impaired hind limb function (result of the pharmacological effect on the muscle). The NOAEL for fertility and general reproduction performance was 8 Units/week for females and 5 Units/week for males.

Teratogenic Effects: DYSPORT AESTHETIC was not teratogenic when evaluated in rats and rabbits. In rats, DYSPORT AESTHETIC was administered at doses of 0.5, 1.5 and 5 Units daily from Gestation Days 6-17. Additional groups of animals received intermittent doses of 10 Units on Days 6 and 12 of gestation. There was a slight increase in fetal resorptions at the high doses of 5 Units daily and 10 Units intermittently. In rabbits, DYSPORT AESTHETIC was administered at doses of 1, 10 and 20 Units daily from Gestation Days 6-19. Additional groups of animals received intermittent doses of 40 Units on Days 6 and 13 of gestation. All animals treated at 20 Units daily died or were sacrificed in a moribund condition, with some animals aborting. C-section data revealed comparable rates of pre-and post-implantation loss across the surviving groups. Fetal survival was not affected.

Reproductive and Developmental Effects: In a study evaluating postnatal effects, pregnant rats were given weekly doses of 1, 2.5, 5 and 10 Units from Day 6 of gestation through weaning of the litters (21 days postpartum). There was no effect of treatment on in utero survival. Evaluation of the offspring showed no effects on survival, body weights, sexual maturation, post-weaning development, mating performance or fertility. All offspring appeared normal.

Animal Toxicity Studies: DYSPORT AESTHETIC has been evaluated in both single dose and repeated dose studies in rats. In the single dose study, DYSPORT AESTHETIC was administered as a single intramuscular injection into the left gluteus muscle at doses of 2 or 6 Units. To evaluate reversibility of effects, subgroups of animals were sacrificed after 7, 30, 60 and 90 days of observation. No adverse systemic signs were observed, and there were no local reactions at the site of injection. Treatment related effects were limited to a reduction in the size and weight of the injected muscle, considered to be a pharmacological effect of the drug. Muscle size reduction was noted at Day 7 and Day 30 for animals treated with 6 Units and 2 Units, respectively. This was histologically confirmed as a reduction in muscle fiber size. By 90 days, muscle fiber size and resultant weights were approaching normal levels for animals treated at 2 Units, but fiber size reductions were still evident for animals treated with 6 Units. Special evaluations looking at nerves serving these muscles showed the expected disorganization early in the study, but normal nerve-muscle morphology was returning by 90 days.

In a chronic toxicity study in rats, DYSPORT AESTHETIC was administered at 1, 4 and 12 Units given as injections at four week intervals for six injections. A fourth group of male and female animals receiving 12 U/adm. as 5 injections were subjected to a one month recovery period. Two control groups received the placebo on the same regimens. There was no indication of systemic toxicity at any dose and there were no signs of local irritation at the injection site. Reduced muscle size was evident at 4 and 12 Units following the first injection, but generally not evident at 1 Unit until the fifth injection. As expected there was histological evidence of atrophy of muscle fibers accompanied by minimal to moderate focal fatty infiltration

and slight to minimal focal interstitial fibrosis at 1, 4 and 12 Units. Animals treated at 12 Units showed reduced body weight gain or body weight loss over the two week period following each dose with no evidence of recovery of the muscle in the rats treated at 12 Units and terminated one month after the fifth injection.

Ocular or Dermal Irritation: A local tolerance study in rabbits showed no adverse effects when instilled into the eye. There was no evidence of local effects at the site of injection in any of the above described toxicity and reproduction studies.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PrDYSPORT AESTHETIC®

(abobotulinumtoxinA) for injection

Read this carefully before you start taking **DYSPORT AESTHETIC** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **DYSPORT AESTHETIC**.

Serious Warnings and Precautions

- **DISTANT SPREAD OF TOXIN EFFECT:** The effects of **DYSPORT AESTHETIC** and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.
- The term “Unit” upon which dosing is based, is a specific measurement of toxin activity that is unique to Ipsen’s formulation of abobotulinumtoxinA. Therefore, the units used to describe **DYSPORT AESTHETIC** activity are different from those used to describe that of other botulinum toxin preparations and the units representing **DYSPORT AESTHETIC** activity are not interchangeable with other products.
- **DYSPORT AESTHETIC** should only be administered by physicians with the appropriate qualifications and experience in the treatment and the use of required equipment.

What is **DYSPORT AESTHETIC used for?**

- **DYSPORT AESTHETIC** is used for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) and crow’s feet lines (lateral canthal lines) in adult patients < 65 years of age.

How does **DYSPORT AESTHETIC work?**

DYSPORT AESTHETIC is a drug that temporarily reduces movement of certain upper facial muscles that cause wrinkles. Some patients see results as soon as 24 hours with a median time to onset of three days.

What are the ingredients in **DYSPORT AESTHETIC?**

Medicinal ingredients: abobotulinumtoxinA

Non-medicinal ingredients: Human serum albumin and lactose monohydrate

DYSPORET AESTHETIC comes in the following dosage forms:

DYSPORET AESTHETIC is supplied in a single-use, sterile 300 Unit vial.

Do not use DYSPORET AESTHETIC if:

- You are allergic or sensitive to any of the ingredients
- You have an infection in the muscles where it would normally be injected
- You are allergic to cow's milk protein
- You have any muscle disorders in other parts of your body, including myasthenia gravis, Lambert Eaton Syndrome or amyotrophic lateral sclerosis

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take DYSPORET AESTHETIC. Talk about any health conditions or problems you may have, including if you:

- You have myasthenia gravis or Lambert Eaton Syndrome, amyotrophic lateral sclerosis or any other muscle disorders
- You have received any other botulinum toxin product in the last four months
- You have any eye disorders including drooping eyes, dry eyes
- You have bleeding problems
- You are allergic or sensitive to any botulinum toxin product
- You have an infection at the proposed injection site
- You are scheduled to have surgery using a general anesthetic
- You are taking or are likely to take antibiotics, especially aminoglycoside antibiotics
- You are pregnant or become pregnant while taking this drug.
- You are nursing. It is not known whether this drug is excreted in human milk.
- You have pre-existing swallowing or breathing difficulties.

Other warnings you should know about:

DYSPORET AESTHETIC is for intramuscular use only.

DYSPORET AESTHETIC should only be given by a physician with the appropriate qualifications and experience in the treatment and use of **DYSPORET AESTHETIC**.

Side effects may occur from misplaced injections of **DYSPORET AESTHETIC** temporarily paralyzing nearby muscle groups. There have been very rare reports of side effects that may be related to the spread of botulinum neurotoxin distant from the injection site. These may include excessive muscle weakness, swallowing and breathing difficulties or accidental swallowing of food or drink into the airways, which can be life threatening or fatal. These symptoms have been reported hours to weeks after injection. Patients who receive the recommended doses may very rarely experience excessive muscle weakness.

DYSPORET AESTHETIC may cause loss of strength or general muscle weakness, blurred vision, or drooping eyelids within hours to weeks after injection. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

Seek immediate medical attention if swallowing, speech or respiratory problems arise.

Tell your doctor if you experience any difficulties in swallowing food while on **DYSPORET AESTHETIC**, as it could be related to the dosage. Difficulty in swallowing food, ranging from

very mild to severe, can persist for 2–3 weeks after injection, or longer.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with DYSPORT AESTHETIC:

- The effect of **DYSPORT AESTHETIC** may be increased by aminoglycoside antibiotics (e.g., streptomycin, tobramycin, neomycin, gentamicin, kanamycin, amikacin), spectinomycin, polymyxins, tetracyclines, lincomycin, muscle relaxant, or any other drugs that interfere with neuromuscular transmission.

How to take DYSPORT AESTHETIC:

Usual dose:

DYSPORT AESTHETIC can only be used by healthcare professionals experienced in the application of Botulinum toxin.

The optimum dosage and number of injection sites in the treated muscle will be chosen by your doctor.

Overdose:

Overdose with **DYSPORT AESTHETIC** is a relative term that can reflect undesired aesthetic effect. Symptoms of overdose for this product, as for all botulinum toxins, are related to the dose, the condition being treated and susceptibility of the patient. Symptoms are not apparent immediately after the injection and may include general weakness, drooping eyelid, double vision, swallowing and speech difficulties, and pneumonia.

In case you feel symptoms of overdose please seek medical emergency services immediately or ask your relatives to do so and have yourself admitted to hospital. Medical supervision for up to several days and assisted ventilation may be necessary.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

If you think you, or a person you are caring for, have taken too much **DYSPORT AESTHETIC**, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

What are possible side effects from using DYSPORT AESTHETIC?

These are not all the possible side effects you may have when taking **DYSPORT AESTHETIC**. If you experience any side effects not listed here, tell your healthcare professional.

The most commonly reported side effects ($\geq 3\%$) were:

- Headache
- Injection site pain
- Upper respiratory infection, or sinus infection

The following additional side effects have been reported with **DYSPORT AESTHETIC**:

- Drooping Eyelid (ptosis)
- Eyelid oedema
- Injection site reactions (e.g. bruising, itchy skin, swelling)

- Temporary facial paralysis close to injection site
- Blurred or double vision
- Dry eyes

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

DYSPORE AESTHETIC must be stored under refrigeration at 2–8°C. Protect from light. Once reconstituted, it can be stored under refrigeration at 2–8°C for up to 24 hours. Do not freeze after reconstitution.

Keep out of reach and sight of children.

If you want more information about DYSPORE AESTHETIC:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>; the manufacturer's website <http://www.DysportCanada.ca>, or by calling 1-800-467-2081.

This leaflet was prepared by Ipsen Biopharmaceuticals Canada Inc.

DYSPORE AESTHETIC is a trademark of IPSEN BIOPHARM LTD.

Last Revised: JUL 23, 2021